BTIG analyst Mark Massaro lowered the firm’s price target on Akoya Biosciences to $11 from $14 but keeps a Buy rating on the shares. The company’s Q2 results were a topline beat and it is now in the early phases of a significant new suite of product launches, though the firm’s price target cut reflects the higher share count following its $50M equity offering in Q2, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on AKYA:
- Akoya Biosciences backs FY23 revenue view $95M-$98M, consensus $96.38M
- Akoya Biosciences reports Q2 EPS (51c), consensus (44c)
- Akoya Reports Record Revenue in the Second Quarter of 2023 and Reiterates Full Year 2023 Revenue Guidance
- Akoya announces 1,000 peer-reviewed publications citing Spatial Biology Tech
- Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies